{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"201"}],"units":"Participants"}],"description":"Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples were tested in screening assay, and positive samples were further characterized for antibody titers.","groups":[{"description":"Participants with relapsed/refractory multiple myeloma (RRMM) received 30 minutes intravenous infusion of 2.5 milligram/kilogram (mg/kg) belantamab mafodotin on day 1 of each 21-day cycle","id":"OG000","title":"Belantamab Mafodotin"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Population.","reportingStatus":"POSTED","timeFrame":"Upto approximately 263 weeks","title":"Number of Participants With Post-baseline Positive Anti-Drug Antibody (ADAs) Against Belantamab Mafodotin","type":"SECONDARY","unitOfMeasure":"Participants"}